Barbara Schütt - Concepedia

Author

Barbara Schütt

Bayer (Germany)

Also Known As

B Schutt, B Schütt, B. Schutt, B. Schütt, Barbara Schtt, Barbara Schutt, Barbara Schütt, Schütt, Barbara, T. Faustmann

Publications

289

Citations

H-Index

Concepts

All Affiliations

Bayer (Germany)RAG Aktiengesellschaft (Germany)

About

Barbara Schütt is an author at Bayer (Germany) specializing in medicine, pharmacology, and endocrinology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	50
2	Public Health	2	2	29
3	Engineering	1	1	19
4	Computer Science	1	1	19
5	Data Science	1	1	19

Barbara Schütt

Publications

248

Citations

H-Index

Page 1

	Year	Citations
Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women Barbara Schütt, Andreas Kaiser, Marcus‐Hillert Schultze‐Mosgau, Human Reproduction	2016	43
Diagnosing deficits in quality of life and providing tailored therapeutic options: Results of a randomised trial in 220 patients with colorectal cancer Monika Klinkhammer‐Schalke, Brunhilde Steinger, Michael Koller, European Journal of Cancer	2020	40
Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol Herbert Wiesinger, Matthias Berse, Stefan Klein, British Journal of Clinical Pharmacology	2015	32
Human studies on abecarnil a new beta‐carboline anxiolytic: safety, tolerability and preliminary pharmacological profile. Theodora Duka, Barbara Schütt, W. Kŕause, British Journal of Clinical Pharmacology	1993	27
Effect of the Novel Selective Progesterone Receptor Modulator Vilaprisan on Ovarian Activity in Healthy Women Barbara Schütt, Marcus‐Hillert Schultze‐Mosgau, Corinna Draeger, The Journal of Clinical Pharmacology	2017	26
1001 Ways of Scenario Generation for Testing of Self-driving Cars: A Survey Barbara Schütt, Joshua Ransiek, Thilo Braun, Automotive EngineeringEngineeringScenario AcquisitionTest Data GenerationSoftware Engineering	2023	19
Protein binding of active ingredients and comparison of serum ethinyl estradiol sex hormone-binding globulin, corticosteroid-binding globulin, and cortisol levels in women using a combination of gestodene/ ethinyl estradiol (Femovan) or a combination of desogestrel/ ethinyl estradiol (Marvelon) and single-dose ethinyl estradiol bioequivalence from both oral contraceptives M. Hümpel, U. Täuber, W. Kuhnz, American Journal of Obstetrics and Gynecology Hormonal ContraceptiveFertilityReproductive HealthOvarian CancerOral Contraceptives	1990	17
Influence of changes in the concentration of sex hormone-binding globulin in human serum on the protein binding of the contraceptive steroids levonorgestrel, 3-keto-desogestrel and gestodene W. Kuhnz, Barbara Schütt, Rolf Woloszczak The Journal of Steroid Biochemistry and Molecular Biology Hormonal ContraceptiveFertilityMedicineHormonal ReceptorReproductive Health	1994	12
Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations. W. Kuhnz, Barbara Schütt, John Power, PubMed	1992	11
Pharmacokinetics and acute toleration of the beta-carboline derivative abecarnil in man. W. Kŕause, Barbara Schütt, Th. Duka PubMed PharmacotherapyExperimental PharmacologyPre-clinical PharmacologyMolecular PharmacologyMedicinal Chemistry	1990	11

Page 1